The development of the reversal of the tumor multidrug resistance

Chinese Pharmacological Bulletin

Volumn 21, Issue 5, 2005, Pages 513-518

  Dai, Chun Ling ^a   Fu, Li Wu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Multidrug resistance; P glycoprotein; Reversal; Therapy; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P;

ARTICLE; CANCER CHEMOTHERAPY; DRUG SENSITIVITY; GENE; GENE OVEREXPRESSION; HUMAN; MDR1 GENE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE REVERSAL; NONHUMAN; TUMOR;

EID: 23444449494     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dorr R, Karanes C, Spier C et al. Phase I/II study of the P-glycoprotein modulator PSC833 in patients with acute myelod leukemia[J]. J Clin Oncol, 2001,19(6):1589-99.
2. Visani G, Milligan D, Leon F et al. Combined action of PSC833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor prognosis acute myeloid leukemia [J]. Leukemia, 2001,15(5):764-71.
3. Bates S E, Bakke S, Kang M et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC833) in renal cell carcinoma[J]. Clin Cancer Res, 2004,10 (14):4724-33.
4. Kankesan J, Vanama R, Yusuf A et al. Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats[J]. Carcinogenesis, 2004,25(3):425 -30.
5. Rago RP, Einstein A Jr, Lush R et al. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer [J]. Cancer Chemother Pharmacol, 2003,51(4):297-305.
6. Toppmeyer D, Seidman AD, Pollak M et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel[J]. Clin Cancer Res, 2002,8(3):670-8.
7. Minderman H, O'Loughlin KL, Pendyala L et al. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing ultidrug resistance protein, and breast cancer resistance protein[J]. Clin Cancer Res, 2004,10(5):1826 -34.
8. Maliepaard M, van Gastelen MA, Tohgo A et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918[J]. Clin Cancer Res, 2001,7(4):935-41.
9. Malingre MM, Beijnen JH, Rosing H et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients[J]. Br J Cancer, 2001,84(1):42-7.
10. Bardelmeijer HA, Beijnen JH, Brouwer KR et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein[J]. Clin Cancer Res, 2000,6(11): 4416-21.
11. Rubin EH, de Alwis DP, Pouliquen I et al. A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies[J]. Clin Cancer Res, 2002,8(12):3710-7.
12. Sandler A, Gordon M, De Alwis DP et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy[J]. Clin Cancer Res, 2004,10(10):3265-72.
13. Callies S, de Alwis DP, Mehta A et al. Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar. 3HCl (LY335979)[J]. Cancer Chemother Pharmacol, 2004,54(1):39-48.
14. van Zuylen L, Sparreboom A, van der Gaast A et al. The orally administered P-glycoprotein inhibitor Rl01933 does not alter the plasma pharmacokinetics of docetaxel[J]. Clin Cancer Res, 2000, 6(4):1365-71.
15. Fu Lw, Deng ZA, Fan W et al. Screening and discovery of novel MDR modifiers from naturally occurring bisbenzylisoquinoline alkaloids [J]. Anticancer Res, 2001,21(4A):2273-80.
16. Newman MJ, Rodarte JC, Benbatoul KD et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance[J]. Cancer Res, 2000,60(11): 2964-72.
17. Guns ES, Denyssevych T, Dixon R et al. Drug interaction studies between paclitaxel (Taxol) and OC144-093-a new modulator of MDR in cancer chemotherapy[J]. Eur J Drug Metab Pharmacokinet, 2002,27(2):119-26.
18. + lymphocytes after oral and intravenous administration[J]. Clin Cancer Res, 2000,6(11):4186-91.
19. Mistry P, Stewart AJ, Dangerfield W et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576[J]. Cancer Res, 2001,61(2):749-58.
20. Thomas H, Steiner JA, Mould GP et al. A phase II pharmacokinetic study of the P-glycoprotein inhibitor, XR9576, in combination with paclitaxel in patients with ovarian cancer[J]. Proc Annu Meet Am Soc Clin Oncol, 2001,20:288.
21. Ferry D, Price L, Atsmon J et al. A phase II. a pharmacokinetic and pharmacodynamic study of the P-glycoprotein inhibitor, XR9576 in patients treated with doxorubicin chemotherapy[J]. Proc Annu Meet Am Assoc Cancer Res, 2001,42:950.
22. Walker J, Martin C, Callaghan R et al. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy[J]. Eur J Cancer, 2004,40(4):594-605.
23. Chen LM, Liang YJ, Fu LW et al. Screening novel, potent multidrug-resistant modulators from imidazole derivatives[J]. Oncol Res, 2004,14(7-8):355-62.
24. Chen LM, Gu LQ, Fu LW et al. Reversal of P-gp mediated multidrug resistance in vitro and in vivo by FG020318[J]. J Pharm Pharmacol, 2004,56(8):1061-6.